Zambon exercises option on Merck reject safinamide as Newron shakes off the old
This article was originally published in Scrip
Zambon has firmed up its collaboration with fellow Italian firm Newron, exercising the option it took out on the late-stage Parkinson's disease treatment safinamide in April (scripintelligence.com, 5 April 2012). Concurrent with the news, Newron reported positive top-line results from the last two Phase III studies of safinamide and said that its long-serving CEO Luca Benatti would be leaving the company to pursue another opportunity. CFO Stefan Weber is to replace him at the top.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.